Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:approves |
gptkb:2018
gptkb:FDA |
| gptkbp:developed_by |
gptkb:Alexion_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
ravulizumab
|
| gptkbp:ingredients |
C6460 H10080 N1716 O2016 S44
|
| gptkbp:is_used_for |
treatment of paroxysmal nocturnal hemoglobinuria
treatment of atypical hemolytic uremic syndrome |
| gptkbp:manager |
intravenous
|
| gptkbp:targets |
complement protein C5
|
| gptkbp:weight |
149,000 Da
|
| gptkbp:bfsParent |
gptkb:Ultomiris
gptkb:C5 |
| gptkbp:bfsLayer |
5
|